X4 is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for the treatment of rare diseases. X4’s pipeline is comprised of first-in-class, oral, small molecule antagonists of chemokine receptor CXCR4, which have the potential to treat a broad range of rare diseases, including primary immunodeficiencies, neutropenia, and certain cancers.
Volume
Today's Open
Previous Close
Dec 9, 2019 7:42 AM EST
Copyright West LLC.
Minimum 15 minutes delayed.
The use of this website is governed by the Terms of Use. By using this website, you acknowledge that you have read the Terms of Use and the disclaimers and caveats contained in this website, and that you accept and agree to be bound by the terms thereof.